Loading company
ArriVent BioPharma, Inc.
AVBP · Nasdaq · ·
Next earnings: November 9, 2026
$29.54+0.7%Sep 29 close
- 1M
- -2.1%
- 6M
- +40.6%
- 1Y
- +60.1%
AVBP · Nasdaq · ·
Next earnings: November 9, 2026
$29.54+0.7%Sep 29 close
ArriVent BioPharma, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$49.9M | -$31.4M | -58.90% |
| Profit per share | -$1.05 | -$0.90 | -16.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
ArriVent BioPharma, Inc. has no earnings call transcript available.
“Our FURVENT and ALPACCA global pivotal trials have the potential to establish firmonertinib as a first-line treatment option for uncommon EGFR mutations in non-small cell lung cancer (NSCLC), addressing a significant unmet need for patients who remain underserved by current therapies,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ArriVent BioPharma, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.